Loading...

EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING

BACKGROUND: Isocitrate dehydrogenase (IDH) mutant tumors represent a distinct subtype among diffuse gliomas, with improved prognosis compared to grade-matched IDH wild-type tumors. As a basis for clinical trial design of IDH-targeting drugs, we sought to describe outcomes exclusively within the glio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Miller, Julie, Loebel, Franziska, Arrillaga-Romany, Isabel, Mordes, Daniel, Lelic, Nina, Batchelor, Tracy, Iafrate, A John, Chi, Andrew, Cahill, Daniel
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2018
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216783/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.338
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!